Entasis Therapeutics Holdings Inc (ETTX)

Etorro trading 970x250
Entasis Therapeutics Holdings Inc (ETTX) Logo

About Entasis Therapeutics Holdings Inc

Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. It is involved in developing Sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that has completed Phase II clinical trial for the treatment of multi-drug resistant Acinetobacter infections; Zoliflodacin, a novel orally administered molecule that has completed Phase II clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant Gram-negative infections. The company has collaboration agreements with Zai Lab (Shanghai) Co., Ltd. for developing SUL-DUR. Entasis Therapeutics Holdings Inc. was incorporated in 2018 and is based in Waltham, Massachusetts. Address: 35 Gatehouse Drive, Waltham, MA, United States, 02451

Entasis Therapeutics Holdings Inc News and around…

Latest news about Entasis Therapeutics Holdings Inc (ETTX) common stock and company :

Week In Review: China's Hansoh Signs Two siRNA Deals Worth $1.7 Billion
23 Oct, 2021 FinancialContent

Hansoh announced a $1.3 billion deal to develop three siRNA candidates from London's Silence Therapeutics. In the past week, Hansoh also revealed a $456 million deal with Korea's OliX Pharma for China rights to three other siRNA molecules.

12 Health Care Stocks Moving In Friday's Pre-Market Session
22 Oct, 2021 FinancialContent

Gainers Nutriband (NASDAQ:NTRB) shares rose 15.52% to $6.72 during Friday's pre-market session. The market value of ...

Entasis' (ETTX) Phase III Study on Infection Drug Meets Goal
20 Oct, 2021 Yahoo! Finance

Entasis' (ETTX) phase III ATTACK study achieves primary endpoint. The study evaluates its investigational combo drug SUL-DUR in infections caused by Acinetobacter baumannii.

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
20 Oct, 2021 FinancialContent

Gainers F-star Therapeutics (NASDAQ:FSTX) shares increased by 18.74% to $7.6 during Wednesday's pre-market session. ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
20 Oct, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips I hope you're ready for another busy day of trading because we're starting it with the biggest pre-market stock movers for Wednesday. The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

16 Stocks Moving in Wednesday's Pre-Market Session
20 Oct, 2021 FinancialContent

Gainers Troika Media Group, Inc. (NASDAQ: TRKA) rose 27.3% to $2.05 in pre-market trading after surging around 9% on Tuesday. The ...

Zai Lab Says Novel Antibacterial Effective Against a Drug Resistant Pathogen
20 Oct, 2021 FinancialContent

Shanghai Zai Lab reported positive results from a Phase III trial of a novel antibacterial in patients with infections caused by Acinetobacter baumannii. In 2018, Zai acquired China/Southeast Asia rights to SUL-DUR in a $100 million agreement with Entasis Therapeutics of Cambridge, MA. In the jointly conducted global trial, SUL-DUR showed significant improvement in clinical response for SUL-DUR over colistin, while reducing nephrotoxicity. Acinetobacter is a Gram-negative human pathogen that can acquire high rates of multidrug resistance. More details.... Stock Symbols: (NSDQ: ZLAB; HKEX: 9688) (NSDQ: ETTX) Share this with colleagues:

12 Health Care Stocks Moving In Tuesday's After-Market Session
19 Oct, 2021 FinancialContent

Gainers Sesen Bio (NASDAQ:SESN) stock moved upwards by 17.82% to $1.19 during Tuesday's after-market session. This security traded ...

10 Best Penny Stocks To Buy Now According To Analysts
19 Oct, 2021 FinancialContent
Zai Lab and Entasis Therapeutics Announce Positive Topline Results for Sulbactam-Durlobactam (SUL-DUR) from Phase 3 ATTACK Trial
19 Oct, 2021 Yahoo! Finance

SUL-DUR first to achieve statistical non-inferiority in 28-day all-cause mortality in carbapenem-resistant Acinetobacter (CRAB) patients Statistically significant difference in clinical cure at Test of Cure vs. colistin Favorable safety profile with statistically significant reduction in nephrotoxicity SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceut

The Daily Biotech Pulse: Entasis, Dermata Spike Higher On Positive Readouts, J&J Q3 EPS Beats Estimates, Wave Life Sciences Regains Right To CNS Portfolio
19 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Entasis Announces Positive ...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
19 Oct, 2021 FinancialContent

Gainers Entasis Therapeutics Hldg (NASDAQ:ETTX) shares moved upwards by 16.72% to $3.63 during Tuesday's pre-market ...

Entasis Shares Rally On Positive Data From Drug-Resistant Bacterial Infection Candidate
19 Oct, 2021 FinancialContent

Entasis Therapeutics Holdings Inc(NASDAQ: ETTX)announced topline resultsfrom its Phase 3 ATTACK trial of ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
19 Oct, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! It's time to get right back into investing with a look at the biggest pre-market stock movers for Tuesday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

18 Stocks Moving in Tuesday's Pre-Market Session
19 Oct, 2021 FinancialContent

Gainers Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL) rose 26.1% to $2.03 in pre-market trading after surging 18% on ...

Entasis Therapeutics announces positive topline results for sulbactam-durlobactam (SUL-DUR) from Phase 3 ATTACK trial
18 Oct, 2021 Yahoo! Finance

SUL-DUR first to achieve statistical non-inferiority in 28-day all-cause mortality in carbapenem-resistant Acinetobacter (CRAB) patientsStatistically significant difference in clinical cure at Test of Cure vs. colistinFavorable safety profile with statistically significant reduction in nephrotoxicityTargeting NDA submission in mid-2022Management to host a conference call on October 19, 2021, at 8:00am ET WALTHAM, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq

12 Health Care Stocks Moving In Monday's After-Market Session
27 Sep, 2021 FinancialContent

Gainers Paratek Pharmaceuticals (NASDAQ:PRTK) shares moved upwards by 9.7% to $5.65 during Monday's after-market session. Today's ...

Entasis Therapeutics to Participate in the Cantor Fitzgerald Virtual Global Healthcare Conference
23 Sep, 2021 FinancialContent
The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
21 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Making Money With Penny Stocks During a Stock Market Crash
20 Sep, 2021 FinancialContent
12 Health Care Stocks Moving In Friday's Intraday Session
17 Sep, 2021 FinancialContent

Gainers Corvus Pharmaceuticals (NASDAQ:CRVS) shares rose 78.31% to $4.03 during Friday's regular session. The current volume of ...

Why Are Entasis Therapeutics Shares Moving Higher On Thursday?
16 Sep, 2021 FinancialContent

Entasis Therapeutics Holdings Inc(NASDAQ: ETTX) stock is up sharplyafter the journal Nature publishedan article on ...

12 Health Care Stocks Moving In Thursday's Intraday Session
16 Sep, 2021 FinancialContent

Gainers Leap Therapeutics (NASDAQ:LPTX) stock moved upwards by 27.72% to $2.46 during Thursday's regular session. As ...

Profile of Entasis Therapeutics ETX0462 Candidate Published in the Journal Nature
15 Sep, 2021 FinancialContent

Publication Details the Discovery and Preclinical Profile of ETX0462, a First-in-Class Candidate Against Multidrug-Resistant Pathogens

Entasis Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
09 Sep, 2021 FinancialContent
Entasis Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
09 Sep, 2021 Yahoo! Finance

WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today that management will participate in the upcoming H.C. Wainwright 23rd Annual Global Investment Conference. Details of the Company’s participation are as follows: Conference: H.C. Wainwright 23rd Annual Global Investment ConferenceDates: September 13-15, 2021Format:

Will Entasis Therapeutics Holdings (NASDAQ:ETTX) Spend Its Cash Wisely?
14 Aug, 2021 Yahoo! Finance

We can readily understand why investors are attracted to unprofitable companies. For example, although...

12 Health Care Stocks Moving In Friday's After-Market Session
13 Aug, 2021 FinancialContent

Gainers Cellect Biotechnology (NASDAQ:APOP) shares rose 22.05% to $4.76 during Friday's after-market session. At the close, Cellect ...

The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
12 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Entasis Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
11 Aug, 2021 FinancialContent

Entasis Therapeutics Holdings Inc (ETTX) is a NASDAQ Common Stock listed in , ,

970x250